Compass Pathways announces parallel treatment results with COMP360 for patients continuing to take SSRI-based antidepressants.
Gold prices moving higher after U.S. CPI rises 6.8%, biggest jump since 1982
Gold prices are pushing higher, following a stronger-than-expected rise in U.S. consumer prices.
Numinus Wellness Inc. Reports Q4 and Year End 2021 Results
Numinus reports strong revenue growth, a gross profit on Q4 clinic operations, and cash position of CAD$59.2 million.
Mydecine Secures Financing and Provides Company Update on Clinical Trials, Drug Development and Technology Initiatives
Mydecine raises CAD$.5.5 million via convertible debenture and provided a corporate update, including news on its future Phase 2/3 smoking cessation trial.
MindMed Engages in Productive Pre-Submission Meeting with FDA for Development of the MindMed Session Monitoring System
MindMed announces successful discussions with the FDA involving its MindMed Session Monitoring System device for clinical use.
Gold price near steady as risk appetite growing
Buying interest is being limited in safe-haven gold and silver as trader and investor risk appetite seems to be growing keener by the day.
MINDCURE's iSTRYM Platform: Psychedelics Penetration Is Only The Beginning
MINDCURE's iSTRYM digital therapeutics platform is a first-mover in supplying this critical IT to mental health treatment. But that's only the beginning of its potential.
Gold, silver up, following solid price gains in crude oil
A strong rally in raw commodity sector leader crude oil early this week is supporting upside price action in the metals markets.
More Outstanding Results With Psychedelics Research, Even More Outstanding Value For Investors
GH Research just released outstanding clinical results for its psychedelic-assisted therapy for TRD. Markets badly mis-pricing these stocks at present.
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Mydecine files a detailed patent application covering "multiple families of psilocin analogs."
GH Research Reports Third Quarter 2021 Financial Results and Provides Business Updates
GH Research reports its Q3 for 2021 and announces VERY successful results from its Phase 2a trial for Treatment Resistant Depression (TRD).
Novamind Opens New Clinic with Specialized Focus on Substance Use Disorders
Novamind's new Salt Lake City clinic will specialize in treating substance abuse disorders.
